3-O-Acetyl-beta-boswellic acid
CAS No. 5968-70-7
3-O-Acetyl-beta-boswellic acid( 3-Acetyl-beta-boswellic acid )
Catalog No. M24594 CAS No. 5968-70-7
3-O-Acetyl-beta-boswellic acid has antitumor activity, it inhibits synthesis of DNA, RNA and protein in human leukemia HL-60 cells in a dose dependent manner with IC50 values ranging from 0.6 to 7.1 microM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 107 | In Stock |
|
| 10MG | 160 | In Stock |
|
| 25MG | 269 | In Stock |
|
| 50MG | 390 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name3-O-Acetyl-beta-boswellic acid
-
NoteResearch use only, not for human use.
-
Brief Description3-O-Acetyl-beta-boswellic acid has antitumor activity, it inhibits synthesis of DNA, RNA and protein in human leukemia HL-60 cells in a dose dependent manner with IC50 values ranging from 0.6 to 7.1 microM.
-
Description3-O-Acetyl-beta-boswellic acid has antitumor activity, it inhibits synthesis of DNA, RNA and protein in human leukemia HL-60 cells in a dose dependent manner with IC50 values ranging from 0.6 to 7.1 microM.
-
In Vitro——
-
In Vivo——
-
Synonyms3-Acetyl-beta-boswellic acid
-
PathwayCell Cycle/DNA Damage
-
TargetDNA/RNA Synthesis
-
RecptorDNA/RNA Synthesis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number5968-70-7
-
Formula Weight498.74
-
Molecular FormulaC32H50O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@H]1[C@H](C)[C@H]2C3=CC[C@H]([C@@](C)(CC[C@H]4OC(C)=O)[C@@H](CC5)[C@@]4(C)C(O)=O)[C@]5(C)[C@]3(C)CC[C@@]2(C)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture.Planta Med. 1998 May;64(4):328-31.
molnova catalog
related products
-
TFMB-(S)-2-HG
TFMB-(S)-2-HG (TFMB S 2 HG) is a highly effective inhibitor of TET2, the 5'-methylcytosine hydroxylase. Additionally, it significantly inhibits the EglN prolyl hydroxylases.
-
Actinomycin D
A chemotherapy agent that has the ability to inhibit transcription.
-
JH-RE-06
JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.
Cart
sales@molnova.com